텔콘RF제약
Humanigen, Inc., (Nasdaq: HGEN) ("Humanigen"), a clinical stage biopharmaceutical company focused on preventing and treating an immune hyper-response called 'cytokine storm' with its lead drug candidate lenzilumab(TM), today announced that the Company's management will present or participate in panel discussions at the following upcoming virtual investor conferences:
ROTH Capital Healthcare Event -- COVID-19 Therapeutics in Development (October 28, 2020)
전문가방송
연관검색종목 04.26 00:30 기준
0/1000 byte